NCT01952054View on ClinicalTrials.gov

Denosumab for Breast Cancer With Bone Mets

PHASE2TerminatedINTERVENTIONAL

Enrollment

7

Participants

Timeline

Start Date

February 9, 2015

Primary Completion Date

October 10, 2018

Study Completion Date

October 10, 2018

Conditions

Breast Cancer

Interventions

DRUG

Denosumab

120 mg subcutaneously on Day 1 of every 28 day cycle.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Amgen

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER